Top Page
China Molybdenum Co
(3993)
China Molybdenum Co (3993) vs. iShares MSCI Hong Kong ETF (EWH)
China Molybdenum Co Business Overview & Revenue Model
China Molybdenum Co Earnings Call Summary
China Molybdenum Co Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 204.98B | 213.03B | 186.27B | 172.99B | 173.86B | 112.98B |
| Gross Profit | 36.42B | 35.25B | 17.83B | 16.06B | 16.32B | 8.45B |
| EBITDA | 34.52B | 31.39B | 20.17B | 17.10B | 17.11B | 9.01B |
| Net Income | 16.79B | 13.53B | 8.25B | 6.07B | 5.11B | 2.33B |
Balance Sheet | ||||||
| Total Assets | 178.63B | 170.24B | 172.97B | 165.02B | 137.45B | 122.44B |
| Cash, Cash Equivalents and Short-Term Investments | 40.17B | 36.94B | 39.00B | 36.88B | 31.44B | 24.38B |
| Total Debt | 28.95B | 29.64B | 50.86B | 48.35B | 46.86B | 47.66B |
| Total Liabilities | 89.58B | 84.29B | 101.01B | 102.98B | 89.19B | 75.11B |
| Stockholders Equity | 73.80B | 71.02B | 59.54B | 51.70B | 39.85B | 38.89B |
Cash Flow | ||||||
| Free Cash Flow | 28.54B | 27.49B | 2.62B | 4.94B | 1.91B | 870.66M |
| Operating Cash Flow | 33.62B | 32.39B | 15.54B | 15.45B | 6.19B | 8.49B |
| Investing Cash Flow | 3.55B | -1.16B | -10.66B | -7.37B | -4.89B | ― |
| Financing Cash Flow | -39.43B | -30.57B | -8.61B | -2.10B | 7.89B | 422.30M |
China Molybdenum Co Technical Analysis
China Molybdenum Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $359.07B | 15.61 | 27.23% | 1.67% | -2.42% | 38.68% | |
71 Outperform | $3.18B | 8.58 | 4.82% | 6.42% | 160.79% | -28.92% | |
70 Outperform | HK$33.36B | 11.83 | 24.57% | 1.70% | 60.77% | 100.45% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
59 Neutral | HK$91.58B | -33.27 | -4.63% | 3.03% | -39.59% | 69.00% | |
58 Neutral | HK$34.03B | 33.62 | 36.46% | 1.43% | 31.24% | 58.18% | |
51 Neutral | HK$2.12B | ― | -14.35% | ― | -31.35% | -71.37% |
China Molybdenum Co Corporate Events
China Molybdenum Co, a joint stock company incorporated in the People’s Republic of China, has announced the composition of its board of directors and their roles within various committees. The board comprises executive, non-executive, and independent non-executive directors, with specific members assigned to the Audit and Risk, Nomination and Governance, Remuneration, and Strategic and Sustainability Committees. This announcement provides clarity on the governance structure of the company, which is crucial for stakeholders to understand the decision-making framework and oversight within the organization.
The most recent analyst rating on (HK:3993) stock is a Buy with a HK$17.50 price target. To see the full list of analyst forecasts on China Molybdenum Co stock, see the HK:3993 Stock Forecast page.
CMOC Group Limited has announced the resignation of its Executive Director and President, Mr. Sun Ruiwen, and Vice President and Chief Commercial Officer, Mr. Kenny Ives, citing personal work reasons and family commitments, respectively. The company assures that these changes will not affect its daily operations or board functionality. Additionally, Mr. Peng Xuhui has been proposed as a new Executive Director, bringing extensive experience in corporate management and strategic planning, which is expected to bolster the company’s leadership and operational strategies.
The most recent analyst rating on (HK:3993) stock is a Buy with a HK$17.50 price target. To see the full list of analyst forecasts on China Molybdenum Co stock, see the HK:3993 Stock Forecast page.
CMOC Group Limited has announced its unaudited financial results for the third quarter ending September 30, 2025. The company reported a slight decrease in operating revenue by 2.36% compared to the same period last year, while total profit and net profit attributable to shareholders saw substantial increases of 64.37% and 96.40%, respectively. The financial report highlights a robust growth in profitability despite a decline in revenue, indicating improved operational efficiency and cost management. This performance may strengthen CMOC’s position in the mining industry and provide positive implications for its stakeholders.
The most recent analyst rating on (HK:3993) stock is a Buy with a HK$17.50 price target. To see the full list of analyst forecasts on China Molybdenum Co stock, see the HK:3993 Stock Forecast page.
CMOC Group Limited has announced an online briefing session for its 2025 third quarterly results, scheduled for October 28, 2025. The session aims to facilitate interaction with investors, allowing them to appraise the company’s performance and operations. Independent non-executive directors and management will participate, providing an opportunity for stakeholders to engage and have their questions addressed.
The most recent analyst rating on (HK:3993) stock is a Buy with a HK$17.50 price target. To see the full list of analyst forecasts on China Molybdenum Co stock, see the HK:3993 Stock Forecast page.
China Molybdenum Co, a joint stock company incorporated in the People’s Republic of China, held its 2025 first extraordinary general meeting (EGM) on October 15, 2025, in Shanghai. The meeting saw a significant shareholder turnout, with approximately 68.62% of total issued shares represented. Key resolutions, including the approval of the H Share Restricted Share Scheme and related mandates, were passed with overwhelming support. The EGM proceedings complied with relevant legal and corporate governance requirements, and the voting process was overseen by representatives from shareholders, legal, and auditing firms.
The most recent analyst rating on (HK:3993) stock is a Buy with a HK$17.50 price target. To see the full list of analyst forecasts on China Molybdenum Co stock, see the HK:3993 Stock Forecast page.
CMOC Group Limited has announced a board meeting scheduled for 24 October 2025 to discuss and approve the publication of its quarterly results for the nine months ending 30 September 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:3993) stock is a Buy with a HK$16.50 price target. To see the full list of analyst forecasts on China Molybdenum Co stock, see the HK:3993 Stock Forecast page.
China Molybdenum Co, operating as CMOC Group Limited, has announced its 2025 first extraordinary general meeting (EGM) to be held in Shanghai, China. The meeting will focus on approving several special resolutions, including the H Share Restricted Share Scheme and related mandates. These resolutions aim to enhance the company’s share management and governance structure, potentially impacting shareholder value and the company’s strategic positioning in the market.
The most recent analyst rating on (HK:3993) stock is a Buy with a HK$13.50 price target. To see the full list of analyst forecasts on China Molybdenum Co stock, see the HK:3993 Stock Forecast page.
China Molybdenum Co, a company incorporated in the People’s Republic of China, has proposed the adoption of an H Share Restricted Share Scheme. This initiative aims to align key personnel with the company’s long-term goals, recognize high-performing employees, and attract talent. The scheme involves issuing new shares and requires shareholder approval. It is designed to deepen the connection between the company and its employees, ensuring a strong talent foundation for strategic and operational objectives.
The most recent analyst rating on (HK:3993) stock is a Buy with a HK$13.50 price target. To see the full list of analyst forecasts on China Molybdenum Co stock, see the HK:3993 Stock Forecast page.
The recent earnings call of China Molybdenum (CMOC) painted a largely positive picture, underscored by record profits and a robust cash flow. The company reported strategic advancements through acquisitions and operational efficiencies, while maintaining strong ESG practices. Despite facing challenges in the trading business and cobalt sales due to external factors, the overall sentiment was optimistic, suggesting a strong performance outlook.
China Molybdenum (CMOC) is a leading global mining company engaged in the production and trading of non-ferrous metals, including copper, cobalt, molybdenum, tungsten, and niobium, with operations spanning across Asia, Africa, South America, Oceania, and Europe. In its latest interim earnings report for the first half of 2025, CMOC announced a record high net profit attributable to the parent company of RMB 8.671 billion, marking a significant 60.07% increase year-on-year. The company’s operating revenue reached RMB 94.773 billion, while operating cash flow increased by 11.40% to RMB 12.009 billion, demonstrating robust financial performance and liquidity. Key highlights include the completion of more than half of the annual production targets for all major products, with notable increases in copper and cobalt output, and strategic expansion into gold resources through the acquisition of the Cangrejos Gold Mine in Ecuador. Looking forward, CMOC aims to enhance its global business layout and maintain its competitive edge through continued organizational upgrades, technological innovations, and a focus on sustainable practices, as reflected in its strong ESG ratings.
CMOC Group Limited announced its unaudited consolidated financial results for the first half of 2025, prepared in accordance with the relevant disclosure requirements of the Hong Kong Stock Exchange. The results have been reviewed by the company’s audit and risk committee, ensuring compliance with accounting standards. The interim report, which will be available to shareholders and on the company’s website, highlights the company’s commitment to transparency and accurate financial reporting. However, the report has not been audited, and no profit distribution or capital conversion from capital reserve has been proposed for the reporting period.
The most recent analyst rating on (HK:3993) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on China Molybdenum Co stock, see the HK:3993 Stock Forecast page.
CMOC Group Limited has announced a briefing session to discuss its interim results for the first half of 2025. The session, scheduled for August 25, 2025, will be conducted online via the SSE Roadshow platform, allowing investors to engage with the company’s management and independent directors. This initiative aims to enhance transparency and provide stakeholders with insights into the company’s performance and future prospects.
The most recent analyst rating on (HK:3993) stock is a Buy with a HK$8.00 price target. To see the full list of analyst forecasts on China Molybdenum Co stock, see the HK:3993 Stock Forecast page.
CMOC Group Limited has announced a board meeting scheduled for August 22, 2025, to discuss and approve the interim results for the first half of the year ending June 30, 2025. This meeting is significant for stakeholders as it will provide insights into the company’s performance and strategic direction for the upcoming months.
The most recent analyst rating on (HK:3993) stock is a Buy with a HK$8.00 price target. To see the full list of analyst forecasts on China Molybdenum Co stock, see the HK:3993 Stock Forecast page.